

## GAD-Symptoms (Adherence-Priming)

	Individual manifestation of GAD and comorbide symptoms		How to address within the MAW-manual?		Was this area topic of the session?				
	Individual Symptoms		Within the sessions	Outside of the sessions	1. sess.	2. sess.	3. sess.	4. sess.	5. sess.
<b>1</b>									
<b>2</b>									
<b>3</b>									
<b>4</b>									
<b>5</b>									
	<b>S.Nr.</b>	<b>Further symptoms</b>							

**Was this area topic of the session?**

4 = very intense / 3 = intense / 2 = considerable / 1 = a little bit / 0 = not a topic

## Personal and interpersonal strengths (Resource-Priming)

	Manifestation of patients' individual strengths		How to activate and customize within the MAW-manual?		Was this area topic of the session?				
	Individual strengths		Within the sessions	Outside of the sessions	1. sess.	2. sess.	3. sess.	4. sess.	5. sess.
1									
2									
3									
4									
5									
	<b>S.Nr.</b>	<b>Further strengths</b>							

**Was this area topic of the session?**

4 = very intense / 3 = intense / 2 = considerable / 1 = a little bit / 0 = not a topic

*Appendix B. Zero-order correlations between the outcome measures and the composite measure*

Fixed effects	<i>BAI</i>	<i>PSWQ</i>	<i>BDI</i>	<i>SCL-9</i>	<i>Outcome Composite</i>
BAI					.81
PSWQ	.54				.78
BDI	.65	.55			.88
SCL-9	.66	.60	.74		.87
RES	-.47	-.54	-.64	-.54	.77

For all correlations:  $p < .001$

*Appendix C. Growth models from intake to 6-months follow-up assessment split into the single outcome measures.*

	BAI		PSWQ		BDI-II		GSI		RES		Composite	
	<i>Coeff (SE)</i>	<i>t-ratio</i>	<i>Coeff (SE)</i>	<i>t-ratio</i>	<i>Coeff (SE)</i>	<i>t-ratio</i>	<i>Coeff (SE)</i>	<i>t-ratio</i>	<i>Coeff (SE)</i>	<i>t-ratio</i>	<i>Coeff (SE)</i>	<i>t-ratio</i>
Fixed effect												
For intake												
Base ( $\beta_{00}$ )	22.5 (2.8)		63.7 (1.5)		21.6 (2.3)		17.8 (1.3)		111.4 (7.1)		57.6 (2.0)	
Adherence priming ( $\beta_{01}$ )	0.9 (3.4)	0.3	-0.2 (2.2)	0.1	-4.7 (2.9)	1.6+	-3.3 (2.2)	1.5+	4.5 (8.8)	0.5	-2.3 (2.7)	0.9
Resource priming ( $\beta_{02}$ )	1.4 (3.4)	0.4	1.7 (2.3)	0.8	0.7 (3.2)	0.1	-1.5 (2.0)	0.7	-3.1 (9.9)	0.3	0.4 (3.0)	0.1
For linear growth												
Base ( $\beta_{10}$ )	-40.7 (7.5)		-28.5 (5.4)	5.3 ***	-26.3 (8.0)	3.3***	-23.3 (6.4)	3.6***	93.5 (21.7)	4.2***	-33.4 (6.9)	4.9***
Adherence priming ( $\beta_{11}$ )	18.6 (10.3)	1.8*	14.1 (8.7)	1.6+	15.9 (11.0)	1.5+	21.0 (8.4)	2.5**	-34.5 (25.7)	1.3+	19.9 (8.9)	2.2*
Resource priming ( $\beta_{12}$ )	7.6 (11.8)	0.6	3.4 (9.2)	0.6	-0.6 (10.7)	0.1	4.5 (8.4)	0.5	-7.2 (30.1)	0.2	5.1 (10.2)	0.5
For quadratic growth												
Base ( $\beta_{20}$ )	32.1 (7.2)		14.8 (5.1)	2.9**	15.0 (7.7)	2.0*	14.2 (5.7)	2.5*	-69.9 (20.6)	3.4**	21.4 (6.7)	3.2**
Adherence priming ( $\beta_{21}$ )	-19.5 (9.7)	2.0*	-10.8 (8.1)	1.3+	-12.2 (10.2)	1.2	-19.1 (7.7)	2.5**	22.5 (24.5)	0.9	-17.0 (8.6)	2.2*
Resource priming ( $\beta_{22}$ )	-12.4 (11.6)	1.2	-4.7 (8.1)	0.6	-1.4 (9.8)	0.1	-3.6 (7.4)	0.5	20.4 (28.6)	0.7	-6.4 (9.0)	0.7
Random effect												
Level 2 intercept ( $r_{0j}$ )	74.5		20.4		47.3		18.5		597.0		45.5	
Level 2 linear slope ( $r_{1j}$ )	50.6		44.8		10.9		4.3		287.5		18.9	
Level 1 ( $e_{1j}$ )	30.0		30.8		39.5		20.9		268.6		28.5	

*dfs for t-ratio = 54; 194*

+ p < 0.10

\* p < 0.05

\*\* p < 0.01

\*\*\* p < 0.001

*Appendix D. Multivariate Analysis of Variance: CTS-G observer ratings*

	Between subjects		Within subjects		Sessions*Group	
	Group		Sessions			
	<i>F (df)</i>	$\eta_p^2$	<i>F (df)</i>	$\eta_p^2$	<i>F (df)</i>	$\eta_p^2$
Multivariate	21.0 (6/42)***	0.76	1.7 (9/198)+	0.07	1.3 (18/198)	0.10
<i>Univariate</i>						
Resource activation	10.8 (2/22)***	0.50	0.4 (3/66)	0.02	0.6 (6/66)	0.05
Session-structuring competence	5.5 (2/22)*	0.33	2.7 (3/66)+	0.11	1.5 (6/66)	0.12
General therapeutic competence	7.6 (2/22)**	0.41	0.8 (3/66)	0.04	0.3 (6/66)	0.02

Pillai's Trace

+  $p < 0.10$

\*  $p < 0.05$

\*\*  $p < 0.01$

\*\*\*  $p < 0.001$